The leading theory of the cause of Alzheimer’s disease is the amyloid hypothesis. Simply put, amyloid plaques (misfolded proteins) build up in the brain and kill brain cells, causing memory loss and other dementia symptoms. Drug makers have been looking for a way to clear the brain of these malicious clumps of protein and have come up with a trifecta of new drugs to do just that.

Clinical trials have shown that aducanumab, lecanemab and donanemab all successfully clear amyloid plaques from the brains of people with early stage Alzheimer’s. All three drugs have now been approved by the US drugs regulator to treat the mind-robbing disease. But are these drugs really a “turning point” in the fight against the disease? Public health expert Sebastian Walsh doesn’t think so. In fact, he thinks it should be the “end of the anti-amyloid drug pathway”.

Poland recently confirmed that Russia has indeed deployed tactical nuclear weapons in Belarus. Read here to find out under what circumstances Russia might use them.

And ever wondered if it’s OK to fish that fly out of your glass of malbec and continue drinking? A microbiologist gives her verdict.

Contact us here to have your event listed.

For sponsorship opportunities, email us here